AU644035C - Quinazolines derivatives for enhancing antitumor activity - Google Patents
Quinazolines derivatives for enhancing antitumor activityInfo
- Publication number
- AU644035C AU644035C AU90592/91A AU9059291A AU644035C AU 644035 C AU644035 C AU 644035C AU 90592/91 A AU90592/91 A AU 90592/91A AU 9059291 A AU9059291 A AU 9059291A AU 644035 C AU644035 C AU 644035C
- Authority
- AU
- Australia
- Prior art keywords
- carbon atoms
- methoxy
- hydrogen
- alkoxy
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000002708 enhancing effect Effects 0.000 title description 3
- 230000000259 anti-tumor effect Effects 0.000 title description 2
- 150000003246 quinazolines Chemical class 0.000 title description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 187
- 229910052739 hydrogen Inorganic materials 0.000 claims description 151
- 239000001257 hydrogen Substances 0.000 claims description 151
- -1 bromo, iodo, nitro, amino Chemical group 0.000 claims description 107
- 150000002431 hydrogen Chemical class 0.000 claims description 104
- 125000003545 alkoxy group Chemical group 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 33
- 125000002947 alkylene group Chemical group 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 12
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 8
- 239000005977 Ethylene Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims description 7
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002516 radical scavenger Substances 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000012458 free base Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940009456 adriamycin Drugs 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229960003048 vinblastine Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- XELRMPRLCPFTBH-UHFFFAOYSA-N quinazoline-2,4-diamine Chemical class C1=CC=CC2=NC(N)=NC(N)=C21 XELRMPRLCPFTBH-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 4
- BNHGVULTSGNVIX-UHFFFAOYSA-N 1-(2-ethoxyethoxy)ethanol Chemical compound CCOCCOC(C)O BNHGVULTSGNVIX-UHFFFAOYSA-N 0.000 description 3
- TUQSVSYUEBNNKQ-UHFFFAOYSA-N 2,4-dichloroquinazoline Chemical class C1=CC=CC2=NC(Cl)=NC(Cl)=C21 TUQSVSYUEBNNKQ-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 description 2
- DGHKCBSVAZXEPP-UHFFFAOYSA-N 2,4-dichloro-6,7-dimethoxyquinazoline Chemical compound ClC1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 DGHKCBSVAZXEPP-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- HNJWKRMESUMDQE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-methylethanamine Chemical compound CNCCC1=CC=C(OC)C(OC)=C1 HNJWKRMESUMDQE-UHFFFAOYSA-N 0.000 description 2
- YPNGRZOYTLZRBD-UHFFFAOYSA-N 2-chloroquinazolin-4-amine Chemical class C1=CC=C2C(N)=NC(Cl)=NC2=C1 YPNGRZOYTLZRBD-UHFFFAOYSA-N 0.000 description 2
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CEIXWJHURKEBMQ-UHFFFAOYSA-N Heliamine Chemical compound C1CNCC2=C1C=C(OC)C(OC)=C2 CEIXWJHURKEBMQ-UHFFFAOYSA-N 0.000 description 2
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 102000053576 human ABCB1 Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- SIQBPWRTJNBBER-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-2-benzazepine Chemical compound C1CCNCC2=CC=CC=C21 SIQBPWRTJNBBER-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- CYZSIZPWTTTXNQ-UHFFFAOYSA-N 2-chloro-4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6,7-dimethoxyquinazoline Chemical compound COC1=C(OC)C=C2C(N3CCC=4C=C(C(=CC=4C3)OC)OC)=NC(Cl)=NC2=C1 CYZSIZPWTTTXNQ-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- RXGAEDUUOOCBQJ-UHFFFAOYSA-N 4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-n-methylquinazolin-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCN(C)C1=NC(N2CC3=CC(OC)=C(OC)C=C3CC2)=C(C=C(OC)C(OC)=C2)C2=N1 RXGAEDUUOOCBQJ-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- UXRLRWMULVYUAU-UHFFFAOYSA-N 6,7-dimethoxyquinazoline;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OC)C(OC)=CC2=C1 UXRLRWMULVYUAU-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101710082602 ATP-binding cassette sub-family B member 6 Proteins 0.000 description 1
- 102100021503 ATP-binding cassette sub-family B member 6 Human genes 0.000 description 1
- PITHJRRCEANNKJ-UHFFFAOYSA-N Aclacinomycin A Natural products C12=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CCC(=O)C(C)O1 PITHJRRCEANNKJ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- IRQXZTBHNKVIRL-GOTQHHPNSA-N Bruceantin Chemical compound CC1=C(O)C(=O)C[C@]2(C)[C@@H]([C@@H](O)[C@@H]3O)[C@@]45CO[C@@]3(C(=O)OC)[C@@H]5[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]4C[C@H]21 IRQXZTBHNKVIRL-GOTQHHPNSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101000677883 Homo sapiens ATP-binding cassette sub-family B member 6 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- IRQXZTBHNKVIRL-UHFFFAOYSA-N NSC 165563 Natural products CC1=C(O)C(=O)CC2(C)C(C(O)C3O)C45COC3(C(=O)OC)C5C(OC(=O)C=C(C)C(C)C)C(=O)OC4CC21 IRQXZTBHNKVIRL-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- HCZCARLOZFORBR-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(4-azido-3-iodophenyl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=C(N=[N+]=[N-])C(I)=C1 HCZCARLOZFORBR-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- IRQXZTBHNKVIRL-AYXPYFKUSA-N bruceantin Natural products CC1=C(O)C(=O)C[C@]2(C)[C@@H]([C@@H](O)[C@@H]3O)[C@@]45CO[C@@]3(C(=O)OC)[C@@H]5[C@@H](OC(=O)C=C(C)C(C)C)C(=O)O[C@@H]4C[C@H]21 IRQXZTBHNKVIRL-AYXPYFKUSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940072360 garamycin Drugs 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 102000056783 human ABCB6 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Description
QUINAZOLINES DERIVATIVES FOR
ENHANCING ANTITUMOR ACTIVITY
Background of the Invention
This invention relates to 2,4-diaminoquinazolines and their use as sensitizers of tumor cells to anticancer agents.
In cancer chemotherapy the effectiveness of anticancer drugs is often limited by the resistance of tumor cells. Some tumors such as of the colon, pancreas, kidney and liver are generally innately resistant, and other responding tumors often develop resistance during the course of chemotherapy. The phenomena of multidrug resistance (MOR) is
characterized by the tumor cell's cross-resistance to structurally unrelated drugs. The drugs which are the target of resistance include adriaraycin, daunomycin, vinblastine, vincristine, actinomycin D and etoposide. The resistance cells are often associated with over- expression of the mdrl gene. This gene product is a family of 140-220 kd trans-membrane phosphoglycoprotein (P-glycoprotein) which functions as an ATP-dependent efflux pump. Thus, it has been postulated that this efflux mechanism keeps the intracellular level of the anticancer drug low, allowing the tumor cells to survive.
In recent years various substances such as verapamil, nifedipine and diltiazem have been used in in vitro experimental systems to reverse the MDR phenomena. More recently some of these agents have
been tested clinically as MDR reversing agents. Little efficacy has been observed with verapamil or trifluoro- perazine. Thus, there is a need for an effective MDR reversing agent.
The 2,4-diaminoquinazolines are prepared by known methods utilizing 2,4-dichloroguinazolines [Postovskii and Goncharova, Zh. Obshch. Khim., 32, 3323 (1962)]. Curd et al. (J. Chem. Soc, 1947, 775) reported the synthesis of 2,4-dichloroquinazolines from the
corresponding 2,4 (1H, 3H)quinazolinedione. The
Wellcome Foundation discloses 2,4-diaminoquinazolines of general structure D as antibacterials [GB patent 806772 (1958)3. Hess [US 3,511,836 (1970)] patented compounds of structures E, F, and G as antihypertensive agents. Wijbe [GB patent 1,390,014 (1975)] patented a process for compounds of structure H and these
compounds are claimed to be antibacterials. Lacefield [US patent 3,956,495 (1976)] describes compounds of the general formula I as antithrombotic agents. Crenshaw
[US patent 4,098,788 (1978)] patented a process for the production of compounds of formula J. Hess [European Patent 0,028,473 (1981)] describes chloro- and alkoxy- substituted 2,4-diaminoquinazolines of formula K. Ife et al. describe compounds of general structur L as inhibitors of gastric acid secretion [WO 89/0527
(1989)]. Compounds of structures M and N were
published as phosphodiesterase inhibitors [Miller, J. Med. Chem., 28, 12 (1985)]. Richter et al. published compounds of structur O as inhibitors of dihydrofolate reductase [J. Med. Chem., 17, 943 (1974)]. In search
of compounds with herbicidal activity Miki et al.
reported the synthesis of 2,4-dialkglaminoquinazolines (P) (Chem. Pharm. Bull. 30, 2313 (1982)]. Arylazido- prazosin (Q) has been shown to bind to P-glycoprotein [Safa et al., Biochem. Biophys. Res. Comm. 166, 259 (1990)].
Summary of the Invention
The compound of the present invention are of the formula
or a pharmaceutically acceptable acid addition salt thereof where X and X1 are each hydrogen, alkyl of one to four carbon atoms, iodo, bromo, nitro, chloro, fluoro, methylthio, amino, alkylamino of one to three carbon atoms, methyl- sulfinyl, aminomethyl, (CH3)2S®, dialkylaxinomethyl of three to seven carbon atoms, hydroxymethyl, morpholino, thio- morpholino, benzoylamino, substituted benzoylamino wherein said substituent is azido, methoxy, methyl, fluoro, chloro or trifluoromethyl, alkanoylamino having two to four carbon atoms, 4-methylpiperazino, piperazino, piperidino, pyrrolidino, dialkylamino of two to six carbon atoms or alkoxy of one to four carbon atoms; X2 is hydrogen, alkyl of one to four carbon atoms or alkoxy of one to four carbon atoms; X and X1 together are ethylenedioxy or methylenedioxy; R1 is alkyl having one to four carbon atoms, cycloalkyl of three to seven carbon atoms, alkoxyalkyl said alkoxy having one to three carbon atoms and said alkyl having two to three carbon atoms or benzodioxan-2-ylmethyl; R2 is hydrogen, alkyl of one to eight carbon atoms or benzyl; R1 and R2 when taken together with the nitrogen atom to which they are attached form
(a) a moiety of the formula
where Q is hydrogen, alkoxy of one to three carbon atoms, hydroxy, alkanoylamino having two to four carbon atoms, alkyl of one to three carbon atoms, bromo, iodo, chloro, fluoro, nitro, morpholino, amino, alkylamino of one to three carbon atoms or dialkylamino of two to six carbon atoms, Q1 is hydrogen, fluoro, chloro, bromo, alkyl having one to three carbon atoms or alkoxy having one to three carbon atoms, Q2 is hydrogen or alkoxy of one to three carbon atoms, Q1 and Q2 together are methylenedioxy or ethylenedioxy, R is hydrogen, alkyl having one to four carbon atoms or alkoxy of one to three carbon atoms, m is an integer of 0-2, p is an integer of 1-2, R 5 is hydrogen or dialkoxybenzyl said alkoxy having one to three carbon atoms and R and R5 together are alkylene having one to three carbon atoms,
(b) 1, 2, 3, 4-tetrahydro-beta-carbol-2-yl or
(c) piperidino of the formula
where R6 is pyridylmethoxy, alkoxyalkyleneoxy said alkoxy having one to three carbon atoms and said alkylene having two to three carbon atoms or benzoxazol-2-ylmethyl
(d) octahydroisoindol-2-yl or
(e) decahydroisoquinol-2-yl;
R3 is
(a) cycloalkyl of three to seven carbon atoms,
(b) benzodioxan-2-ylmethyl
(c) aralkyl of the formula
wherein n is an integer of 1 or 0, W is O, S or a chemical bond, A is alkylene of one to four carbon atoms, Y is hydrogen, alkyl of one to three carbon atoms, fluoro, chloro, bromo, hydroxy, alkoxy of one to three carbon atoms, benzyloxy, nitro, dimethylamino or amino, Y1 is hydrogen, alkoxy of one to three carbon atoms, chloro, fluoro, hydroxy or benzyloxy, Y2 is hydrogen or alkoxy of one to three carbon atoms and Y and Y1 together are methylenedioxy or ethylenedioxy,
(d) aralkyl of the formula
where R7 is hydroxy, alkoxy of one to three carbon atoms or C6H5(CH2)t0, n is 1, t is an integer of 1 or 0, A is alkylene of one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are methylenedioxy or ethylenedioxy,
(e) pyridylalkyl said alkyl having one to four carbon atoms,
(f) alkoxyalkyl said alkoxy having one to three carbon atoms and said alkyl having two to three carbon atoms,
(g) indolylalkyl of the formula
where A is alkylene of one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(h) tetrahydronaphthalene of the formula
where A is alkylene of one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy;
(i) aralkanol of the formula
where W is O, S or a chemical bond and Q3 is hydrogen or alkoxy of one to three carbon atoms,
(j) 2,3-dihydro-2-hydroxyinden-1-yl,
(k) aracycloalkyl of the formula
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(1) indene of the formula
wherein Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(m) naphthyl or
(n) 1-methylpyrrol-2-yl;
R4 is hydrogen or alkyl of one to eight carbon atoms and R3 and R4 taken together with the nitrogen atom to which they are attached form
(a) a tetrahydroisoquinoline of the formula
where Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are methylenedioxy or ethylenedioxy,
(b) piperidino of the formula
wherein R8 is benzyl, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having two to three carbon atoms or alkyl sulfonamide of the formula
where R9 is alkyl of one to four carbon atoms
(c) 3-methyl-3-phenylpiperidino or
(d) piperazino of the formula
where R10 is hydrogen, alkoxycarbonyl of two to six carbon atoms, acyl of one to six carbon atoms, hydroxyalkoxy- carbonyl of three to six carbon atoms, furoyl, benzoxazol-2- yl, pyrimid-2-yl or benzodioxan-2-ylcarbonyl.
A preferred group of compounds are those where X and X1 are each alkoxy of one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
where Q1 is alkoxy of one to three carbon atoms, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
where Y1 and Y2 are each methoxy, n is 0 , W is a chemical bond, A is ethylene and R4 is hydrogen. Especially preferred within this group are the compounds where X is 6 -methoxy, X1 is 7-methoxy, Q is 5-hydroxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2-methoxy and Y2 is 3 -methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7 -methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4 -methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2 -methoxy and Y2 is 3-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q and Q2 are each hydrogen, Q1 is 6-methoxy, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 5-methoxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3 -methoxy and Y2 is 4-methoxy, where X is 6-methoxy, X1 is 7 -methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Q2 is hydrogen, Y is 2-bromo, Y1 is 4 -methoxy and Y2 is 5-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy and where X is 6-methoxy, X1 is 7 -methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4 -methoxy.
A second group of preferred compounds are those where X1 and X2 are each hydrogen, R1 and R2 when taken together
with the nitrogen atom to which they are attached form a moiety of the formula
where Q and Q1 are each alkoxy of one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
wherein Y2 is hydrogen, n is 0, W is a chemical bond and A is ethylene and R4 is hydrogen. Especially preferred within this group are compound where X is 5-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Y is 2-chloro and Y1 is hydrogen, where X is 5-chloro, Q is 6-methoxy, Q1 is 7-methoxy, Y is 2-chloro and Y1 is hydrogen, where X is 5-methyl, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and Y1 is 4-methoxy and where X is 6-dimethylamino, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and Y1 is 4-methoxy.
A third group of preferred compounds are those where X and X1 are each alkoxy of one to four carbon atoms, X2 is
hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
where Q2 is hydrogen, R5 is hydrogen, p is 1-2, R3 is aralkyl of the formula
where Y and Y1 are each alkoxy of one to three carbon atoms, Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R4 is hydrogen. Especially preferred within this group are compounds where X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 1, R is methoxy, m is 0, Y is 2-methoxy and Y1 is 3-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 2, R is hydrogen, m is 1, Y is 3-methoxy and Y1 is 4-methoxy and where X is 6-methoxy, X1 is 7-methoxy, Q is 7-amino, Q1 is hydrogen, R is hydrogen, m is 0, p is 1, Y is 3-methoxy and Y1 is 4-methoxy.
A fourth group of preferred compounds those where X and X1 are each alkoxy of one to four carbon atoms, R1 and R2 when
taken together with the nitrogen atom to which they are attached form a moiety of the formula
where Q and Q1 are each alkoxy of one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
where Q3 and Q4 are each alkoxy of one to three carbon atoms, R7 is methoxy, n is 1, A is methylene and R4 is hydrogen.
Especially preferred within this group is the compound where
X is 6-methoxy, X1 is 7-methoxy, Q is 6-fluoro, R is methoxy,
Q3 is 2-methoxy and Q4 is 3-methoxy.
A fifth group of preferred compounds are those where X1 is alkoxy of one to four carbon atoms, X2 is hydrogen, R1 and
R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
where Q and Q1 are each alkoxy of one to three carbon atoms, Q2 is hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
where Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R, is hydrogen. Especially preferred within this group is the compound where X is 6-chloro, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, R and R5 are each hydrogen, Y is 3-methoxy and Y1 is 4-methoxy.
The present invention also includes a method of inhibiting a P-glycoprotein in a mammal in need of such treatment which comprises administering to said mammal a P-glycoprotein inhibiting amount of a compound of formula I. Preferred is the method where the mammal is a human suffering from cancer and said compound is administered before, with or after the administration to said human of an anticancer effective amount of a chemotherapeutic agent.
Also included is a pharmaceutical composition for administration to a mammal which comprises a P-glycoprotein inhibiting amount of a compound of formula I, a pharmaceutically acceptable carrier and, optionally, an anticancer effective amount of a chemotherapeutic agent.
As previously indicated, the compounds of formula I form pharmaceutically acceptable acid addition salts. Said pharmaceutically acceptable acid addition salts include, but are not limited to, those with HCl, HBr, HNO3, H2SO4, H3PO4, CH3SO3H, p-CH3C6H4SO3H, CH3CO2H, gluconic acid, tartaric acid, maleic acid and succinic acid. In the case of those compounds of the formula (I) which contain a further basic nitrogen, it will, of course, be possible to form diacid addition salts (e.g., the dihydrochloride) as well as the usual monoacid addition salt.
As one skilled in the art recognized, compounds of formula I have the potential for containing asymmetric carbon atoms. All these potential isomers are considered within the scope of the present invention.
The terms "alkyl" and "alkylene" are meant to embrace both straight chained and branched members.
Detailed Description of the Invention
Compounds of the present invention are prepared with the reaction of a 2,4-dichloroquinazoline with an equivalent of an appropriate amine, R1R2NH, followed by the reaction of the product, a 2-chloro-4-amino- quinazoline derivative, with a second equivalent of an appropriate amine, R3R4NH.
In a more detailed description of the procedure, one molar equivalent of an optionally substituted
2,4-dichloroquinazoline and one molar equivalent of a tertiary amine-acid scavenger, such as triethylamine, N-methylmorpholine or diethylisopropylamine and one molar equivalent of an amine, R1 R2NH, are combined in an anhydrous solvent such as dimethylacetamide, dioxane or N-methyl-2-pyrrolidone and maintained at from 0°C to about 25°C for a period of 1 to 48 hours.
The reaction mixture can be filtered and the filtrate concentrated to dryness in vacuo, or the reaction mixture can be quenched in water and the intermediate product either filtered or extracted with a water immiscible solvent such as methylene chloride or ethyl acetate. Removal of the extracting solvent provides the desired product. Frequently, the residual can be induced to crystallize by trituration with an organic solvent, and further purified by recrystallization or column chromatography.
The second step of the sequence leading to the products of the present invention consists of combining one molar equivalent of the appropriate 2-chloro-4- aminoquinazoline with either two molar equivalents of
an amine, R3R4NH, or one equivalent of said amine and one equivalent of a tertiary amine-acid scavenger as described above in a reaction-inert solvent such as ethoxyethoxyethanol, butanol, amyl alcohol or
cyclohexanol for a period of 5 minutes to several hours at reaction temperatures of 100-200°C.
The reaction mixture can be cooled to room temperature and treated with a 1-N solution of an appropriate acid, such as hydrochloric acid to give a precipitate of the desired product as the hydrochloride salt.
Other acids would give the corresponding acid addition salt. In instances where the acid addition salt does not precipitate the free base product can be isolated by chromatographing the crude material on silica gel using an eluant such as chloroform, ethyl acetate, diethyl ether, methanol methylene chloride, ethanol or mixtures thereof and subsequently converted to the acid addition salt product. The products are isolated by removing the eluting solvents in vacuo. Purification of the product can be done by recrystallization.
Generation of the free base from an acid addition salt can readily be carried out by treating an aqueous solution or suspension of the salt with at least one equivalent of an organic or inorganic base followed by extraction of the free base product with a water immiscible solvent such as ethyl acetate or methylene chloride. Removal of the solvent gives the desired base.
Compounds of formula I are inhibitors of the functions of P-glycoprotein, particularly human mdr 1 protein or P-glycoprotein related and membrane
associate proteins which are participating in the
transport of xenobiotics or proteins across membranes e.g., cell membranes of eukariotic and proeukariotic origin e.g., pmfdr, however not exclusive or restricted to these examples.
Compounds enclosed in general formula I are useful in combination chemotherapy of cancer, malaria, viral infections such as AIDS, in therapy of septic shock syndrome or inflammation and may be useful in enhancing the tissue penetration of drugs where the penetration of these xenobiotics is limited due to the presence of P-glycoprotein or P-glycoprotein related functional proteins. Compounds of formula I increase the
activity/efficacy of adriamycin, daunomycin, etoposide, epipodophyllotoxin congoners, actinomycin D, emetin, vincristin, vinblastin, chloroquine, antracyclin antibiotics and of drugs which are structurally and functionally related to the above mentioned examples, in particular when the activity of these drugs has been shown to be limited due to the presence and function of P-glycoprotein, e.g. human mdr 1 protein or
P-glycoprotein related proteins.
The compounds of the present invention are evaluated as potentiators of chemotherapeutic agents using a Cellular Drug Retention Assay. This assay was designed to study the effect of compounds on cellular retention of radiolabeled drug. In this case
14C-adriamycin retention by multidrug resistant human carcinoma cells, KBV1, is measured.
KBV1 cells are routinely grown in tissue culture as monolayers in DMEM high glucose medium containing
1 ug/ml vinblastine 10% heat inactivated fetal calf serum and supplemented with Glutamine, Pen-Strep and Garamycin.
The assay protocol (described below) should be applicable, with minor modifications, to a wide variety of cell lines grown in tissue culture.
Assay Protocol:
(1) Seed replicate 6-well tissue culture plates with 1.2 x 10E6 cells per 2 ml per well in absence of Vinblastine;
(2) Incubate 24 hrs at 37 degrees in humidified incubator (5% CO2);
(3) Aspirate off the spent media and overlay monolayers with 2 ml/well of fresh medium that is 2 uM in Adriamycin (2 uM unlabeled Adriamycin + 20000 cpm of 14C-Adr) and the test agent at concentrations varying from 0 to 100 uM;
(4) Following incubation for 3 hours at 37 degrees in humidified incubator, remove media and wash monolayers twice with 2 ml of ice-cold buffered saline;
(5) Detach monolayers using 0.5 ml of
trypsin/EDTA, collect detached cells and transfer to scintillation vial. Rinse wells once with 0.5 ml of buffered saline and add to same vial containing cells;
(6) Add 5 ml of Beckman Ready-Safe scintillation fluid to vial, vortex and determine radioactivity per sample using a scintillation counter (10 minutes per sample);
(7) For background control: pre-incubate
monolayers at 4 degrees for 15 minutes then remove
media and add fresh ice-cold media containing Adr (see step 3). Following incubation for 3 hours at 4 degrees remove media and wash monolayers twice with 2 ml ice-cold buffered saline, then proceed as in step 5;
(8) Results are expressed as T/C and ED3x values as defined below:
T/C = pmoles Adr per 10E6 cells treated with test agent/
pmoles Adr per 10E6 untreated cells
ED3x = concentration of test agent that
produces a 3 fold increase in cellular accumulation of radiolabeled Adr, i.e. T/C = 3.
Calculations:
Specific cpm = [sample cpm - background cpm] Specific activity = [cpm/total cone, of Adr] pmoles Adr = [specific cpm/specific activity] pmoles Adr per 10E6 cells = [(pmoles Adr per well/number of cells per well) x 10E6 cells]
As previously mentioned compounds of the present invention and salts thereof are useful in potentiating the anticancer effects of chemotherapeutic agents.
Such agents can include adriamycin, daunomycin, aclacinomycin A, actinomycin C, actinomycin D,
mithramycin, toyomycin, vinblastine, maytansine, bruceantin, homoharintonin, anguindin, neocarcino- statin, mitomycin C and anthramycin.
The compounds of the present invention can be administered with, 24 hours before or up to 72 hours after the administration of the chemotherapeutic
agents. When administered with said agents, they can be taken either separately or coadministered in the same formulation.
The compounds of the present invention whether taken separately or in combination with an anti-cancer agent, are generally administered in the form of pharmaceutical compositions comprising at least one of the compounds of formula I and optionally a chemotherapeutic agent, together with a pharmaceutically acceptable vehicle or diluent. Such compositions are generally formulated in a conventional manner utilizing solid or liquid vehicles or diluents as appropriate to the mode of desired administration: for oral administration, in the form of tablets, hard or soft gelatin capsules, suspensions, granules, powders and the like, and, for parenteral administration, in the form of injectable solutions or suspensions, and the like.
For use in the potentiation of anti-cancer agents in a mammal, including man, a compound of formula I is given in an amount of about 0.5-100 mg/kg/day, in single or divided doses. A more preferred dosage range is 2-50 mg/kg/day, although in particular cases, at the discretion of the attending physician, doses outside the broader range may be required. The preferred route of administration is generally oral, but parenteral administration (e.g. intramuscular, intravenous, intradermal) will be preferred in special cases, e.g., where oral absorption is impaired as by disease, or where the patient is unable to swallow.
The present invention is illustrated by the following examples, but is not limited to the details or scope thereof.
EXAMPLE 1
2-(N-Methyl-3,4-dimethoxyphenethylamino)-4-(1,2,3,4- tetrahydro-6,7-dimethoxyisoquinol-2-yl)-6,7-dimethoxy- quinazoline hydrochloride (I: X = 6-CH3O; X1 = 7-CH3O;
X2 = H; R1R2N = 6,7-(CH3O)2-1,2,3,4-tetrahydroiso- quinol-2-yl; R3 = 3,4(CH3O) 2phenethyl; and R4 = CH3)
-----------------------------------------------------------------------------------------------------
A. 2-chloro-4-(1,2,3,4-tetrahydro-6,7-dimethoxy- isoquinol-2-yl)-6,7-dimethoxyquinazoline
To 26.59 g of 2,4-dichloro-6,7-dimethoxyquina- zoline and 20.39 g of triethylamine in 250 ml of warm
dimethylacetamide was added 23.1 g of 1,2,3,4-tetra- hydro-6,7-dimethoxyisoquinoline in 300 ml of dry
dimethylacetamide and the reaction mixture stirred at
room temperatures under exclusion of moisture for 16
hours. The precipitate was filtered and the filtrate
concentrated to dryness under reduced pressure. The
residual product was recrystallized from methanol,
40.6 g, m.p. 183-186ºC.
B. 2-(N-methyl-3,4-dimethoxyphenethylamino)-4- (1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)-
6,7-dimethoxyquinazoline hydrochloride
A mixture of 840 mg of the product of Example 1A
and 1.28 g of N-methyl-3,4-dimethoxyphenethylamine in 1
ml of ethoxyethoxyethanol was stirred under an inert
atmosphere for 1 hour at 150°C. The reaction mixture
was cooled to room temperature and passed through a
column packed with 30 g of silica gel under 2.5
atmosphere of nitrogen pressure with 500 ml of
chloroform. The product was eluted with 2% (V:V)
methanol in chloroform. The fraction containing the
product (Rf 0.47 10% methanol in chloroform on silica) was concentrated in vacuo and the crude residue crystallized from IN hydrochloric acid in methanol- water (1:1, V:V), 271 mg, m.p. 190-192°C, M+ = 575.40.
EXAMPLES 2-71
Employing the procedure of Example 1 and starting with the appropriate starting reagents, the following compounds were prepared as their hydrochloride salt unless otherwise indicated:
Example 2: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O and Y2 = H; m.p. 194-195°C, M+ 560.20.
Example 3: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 185-186°C, M+ 500.30.
Example 4: X = 6-C2H5O; X1 = 7-C2H5O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 121-122°C, M+ 588.30.
Example 5: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y, Y1 and Y2 = H; m.p. 219-226°C,
M+ 500.20.
Example 6: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 - H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-) ; n = 0; Y,
Y1 and Y2 = H; m.p. 199-201°C, M+ 440.20.
Example 7: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 and Y2 = H; m.p. 140-142°C, M+ 471.00.
Example 8: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-) ; n = 0; Y = 2-CH3O; Y and Y2 = H;
m.p. 232.5-234°C, M+ 531.00.
Example 9: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
A = -CH2CH(CH3)-; W = 0; n = 1 ; Y, Y1 and Y2 = H;
m.p. 105-107°C, M+ 545.00.
Example 10: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = 0; n = 0; Y = 2-1; Y1 = 4-1; and Y2 = 6-1;
m.p. 175-180°C, M+ 894.90.
Example 11: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; w = (-); n = 0; Y = 4-CH3O; Y1 and Y2 = H;
m.p. 113-115.5°C, M+ 531.00.
Example 12: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y 5= 4-CH3O; Y1 and Y2 = H; m.p. 204-205°C, M+ 471.00.
Example 13: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 2-Cl; Y1 and Y2 = H;
m.p. 130-132.5°C, M+ 535.00.
Example 14: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-) ; n = 0; Y = 3-CH3O; Y = 4-CH3O; and
Y2 = 5-CH3O; m.p. 217-218°C, M+ 591.10.
Example 15: X, X1, X2 = H; R, R4, R5 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 108-109.5°C
(free base), M+ 501.3.
Example 16: X, X1, X2 = H; R, R4, R5 = H; Q, Q1,
Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O;
Y1 = 4-CH3O; and Y = H; m.p. 123.5-124.5°C (free base), M+ 441.20.
Example 17: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = S; n = 1; Y, Y1 and Y2 = H; m.p. 112-114°C, M+
533.2.
Example 18: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-) ; n = 0; Y = 4-NO2; Y1 and Y2 = H;
m.p. 210-213°C, M+ 546.3.
Example 19: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = (-); n = 0; Y = 2-CH3O; Y = 3-CH3O; and Y2 = H; m.p. 108-111°C, M+ 561.00.
Example 20: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = (-); n = 0; Y = 3-CH3O; Y1 = 5-CH3O; and Y2 = H; m.p. 234-235°C, M+ 561.40.
Example 21: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 4-Cl; and Y1 and Y2 = H;
m.p. 111-113°C, M+ 535.30.
Example 22: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 2-CH3O; Y1 = 5-CH3O; and Y2 = H; m.p. 201-203°C, M+ 561.40.
Example 23: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
A = -(CH2)2-; W = (-); n = 0; Y = 4-CH3; and Y1 and
Y2 = H; m.p. 230-323°C, M+ 515.4.
Example 24: X = 6-CH3O; X1 = 7-CH3O; X2 = 8-CH3O; R,
R4, R5 = H; Q; Q = 6-CH3O; Q1 = 7-CH3O; Q = H;
A = -(CH2)2-; W = (-); n = 0; X = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 180-182°C, M+ 591.10.
Example 25: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; A = -(C H2)2 -;
W = (-); n = 0; Y = 4-C2H5O; Y1 and Y2 = H;
m.p. 105-210°C, M+ 545.00.
Example 26: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y and Y2 = H;
m.p. 109-111°C, M+ 531.00.
Example 27: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 2-Br; Y1 = 4-CH3O; and Y2 = 5-CH3O; m.p. 176-179°C, M+ 641.10.
Example 28: X, X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; R, R4, R5 = H; A = -(C H2)2 -; W = (-); n = 0;
Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H; m.p. 208-209°C, M+ 501.10.
Example 29: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-Cl; Y1 = 4-Cl; and Y2 = H;
m.p. 135-138°C, M+ 569.30.
Example 30: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R4 = H; R5 = 3,4-(CH3O)C6H,CH2-; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -; W = (-); n = 0;
Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 156-159°C,
M+ 711.40.
Example 31: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1= 7-CH3O; Q2 = H; A = -(CH2)2-; W = O; n = 0; Y = 2-Cl; Y1 and Y2 = H; m.p.
126.5-128°C, M+ 535.00.
Example 32: X = 6-CH3O; X = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; A = -(CH2)2-; W = 0; n = 0; Y = 4-Cl; Y1 and Y2 = H; m.p. 218-219°C, M+ 535.00.
SUBSTITUTE
Example 33 : X = 6-CH3O; X = 7-CH3O; X2 = H; R, R4 , R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = - (CH2)2-;
W = 0; n = 0; Y = 4-Cl; Y and Y2 = H; m.p. 120-122°C,
M+ 551.30.
Example 34: X = 6-CH 3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = (-); n = 0, Y + Y1 = 3,4-CH2OCH2-; and Y2 = H; m.p.
231.5-233°C, M+ 545.30.
Example 35: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = 0; n = 0; Y = 4-CH3O; Y1 and Y2 = H;
m.p. 115-119°C, M+ 547.30.
Example 36: X = 6-CH3O; X1 - 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -CH2-;
W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and
Y2 = 4-CH3O; m.p. 176.5-178.5°C, M+ 577.40.
Example 37: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-OH; Y1 = 3-C2H5O; and Y2 = H;
138-142°C, M+ 561.30.
Example 38: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-OH; Y1 = 3-CH3O; and Y2 = H;
m.p. 232-235°C, M+ 547.30.
Example 39: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y = 3-CH3O; Y1 and Y2 = H; m.p. 125.5-141.4°C,
M+ 471.20.
Example 40: X = 6-CH3O; X = 7-CH3O; X = H; R, R4, R5 = H; Q = 6-CH3O; Q 1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
Y = 3-C6H5CH2O; Y1 = 4-C6H5CH2O; and Y2 = H;
m.p. 204-206°C, M+ 713.60.
Example 41: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H;
m.p. 189.5-191.5°C, M 501.30.
Example 42: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 7-CH3O; Q = 8-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O; and Y2 = H; m.p. 195-196°C, M+ 561.30.
Example 43: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 189-191°C, M+ 515.30.
Example 44: X = 6-CH3O; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H; m.p.
212-215°C, M+ 531.00.
Example 45: X = 6-CH3O; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(-CH2)2-;
W = (-); n = 0; Y = 2-Cl; Y1 and Y2 = H;
m.p. 221-223°C, M+ 505.20.
Example 46: X = 6-CH3O; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2-H;
m.p. 206-208°C, M+ 531.20.
Example 47: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
A = -CH(CH3)CH2CH2-; W = (-); n = 0; Y, Y1, Y2 = H; m.p. 198-200°C, M+ 529.00.
Example 48: X = 6-CH3O; X1 = 7-C :Hι3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -CH2-;
W = (-); n = 0; Y = 4-CH3O; Y and Y = H;
m.p. 155-156°C, M+
Example 49: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q = 7-CH3O; Q2 = H; A = -CH2-;
W = (-); n = 0, Y, Y1, R1 = H; m.p. 169-171°C;
M+ 487.00.
Example 50: X = 6-F; X1 = 7-F; X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 112-114°C, M+ 537.3.
Example 51: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-F; Y1 and Y2 = H; m.p. 225-227°C,
M+ 519.30.
Example 52: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; R4 = C2H5; Q = 6-CH3; Q1 = 7-CH3O; Q2 = H;
A = -CH2-; W = (-); n = 0; Y = 4-C2H5O; Y1 and Y2 = H; m.p. 201-203°C, M+ 545.40.
Example 53: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; R4 = C2H5; Q, Q1, Q2 = H; A = -CH2-; W = (-); n = 0; Y = 4-C2H5O-; Y1 and Y2 = H; m.p. 167-168°C,
M+ 485.30.
Example 54: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-OH; Y1 and Y2 = H;
m.p. 151-153°C, M+ 517.30.
Example 55: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-NO2; Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 212-214°C, M+ 546.30.
Example 56: X, X1 = H; X2 = 8-CH3O; R, R4, R. = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H;
m.p. 90-92°C (free base), M+ 531.30.
Example 57: X = 6-CH3; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-Cl; Y1 and Y2 = H; m.p. 212-214°C,
M+ 489.00
Example 58: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 160-162°C, M+ 531.00.
Example 59: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 5-CH3O; C1 , Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 197-198.5°C, M+ 531.00.
Example 60: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 - H; Q = 6-CH3O; Q1 = 8-CH3O, Q = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O; and Y2 = H; m.p. 146-149ºC, M+ 561.30.
Example 61: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 7-C1; Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 190-193°C, M+ 535.00.
Example 62: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 5-CH3O; Q , Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H;
m.p. 199-200°C, M+ 531.00.
Example 63: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 5-CH3O; Q , Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-Cl; Y1and Y2 = H; m.p. 210-211°C,
M+ 505.30.
Example 64: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = C2H5O; R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = 8-CH3O; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O;
Y1 = 4-CH3O; and Y2 = H; m.p. 138-140°C, M+ 635.00.
Example 65: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = CH3O;
R4, R5 = H; Q = 7-CH3O; Q1 = 8-CH3O; Q2 = H;
A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 178-180°C, M+ 591.50.
Example 66: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = C2H5O-; R4, R5 = H; Q = 6-CH3O; Q1, Q2 = H;
A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 86-88°C, M+ 575.40.
Example 67: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = C2H5O-; R4, R5 = H; Q = 7-CH3O; Q1 = 8-CH3O;
Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O;
Y1 = 4-CH3O; and Y2 = H; m.p. 168-169°C, M+ 605.40.
Example 68 : X = H; X1 = 7-CH3O; X2 = 8-CH3O; R, R4 ,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = - (C H2)2 -;
W = (-) ; n = 0 ; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H ; m.p. 138-140°C , M+ 561 . 40.
Example 69 : X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4 ,
R5 = H; Q = 6-CH3O; Q = 7-CH3O; Q2 = 8-CH3O;
A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 157-158°C, M+ 591.30.
Example 70: X = H; X1 = 7-CH3O; X2 = 8-CH3O; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O; and Y2 = H; m.p. 147.5-151°C, M+ 561.40.
Example 71: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(C H2)2 -; W = (-) ; n = 0;
Y = 3-CH3O; Y1 = 4-OH; and Y2 = H; m.p. 169-171.5°C,
M 487.20
EXAMPLES 72-106
Using the procedure of Example 1, and starting with the requisite reagents, the following compounds were prepared as their hydrochloride salts unless
indicated otherwise:
Example 72: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H;
R3NR4 = m.p. 181-182°C
M+ 452.20
Example 73: X = 6-CH3O; X = 7-CH3O; X2 = H; Q, Q1,
Q2 = H;
R3NR4 = CHCH2CH2NH- m.p. 224-225°C
M+ 531.20
Example 74: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = CHCH2CH2NH- m.p. 226-229°C
M+ 531.20
Example 75: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 181-183ºC
M+ 572.30
Example 76: X = 6-CH3O; X 7-CH3O; X2 = H; Q, Q1, Q 2 = H;
R3NR4 = m.p. 154-156°C
M+ 512.10
Example 77: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = m.p. 145.5-148°C
M+ 527.00 Example 78: X = 6-CH3O; X1 = 7-CH3CH2CH2O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 170-171°C
M+ 573.20
Example 79: X 6-C2H5O; X1 = 7-C2H5O; X = H;
Q = 6-CH3O; Q1 7-CH3O; Q = H;
R3NR4 = m.p. 196-200°C
M+ 573.20
Example 80: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 233-235ºC
M+ 540.00
Example 81: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p 133-135.5°C
M+ 555.00
Example 82: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p 225-227°C
M+ 570.20
Example 83: X = 6-CH3O; X1 = 7-CH..O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 200-221°C (dec)
M+ 571.00
Example 84: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 186.5-188°C
(free base)
M+ 502.20 Example 85: X = 6-CH3O; X1 = 7-CH3O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 202.5-204.5°C
M+ 513.20
Example 86: X, X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 158-159°C
(free base)
M+ 484.53 Example 87: X = 6-CH3O; X 7-CH3O; X2 = 8-CH3O;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 214-217ºC
M+ 574.3
Example 88: X, X1, X2 = H; Q = 6-H3O; Q1 = 7-CH3O;
Q2 = H;
R3NR4 = m.p. 148-150°C
(free base)
M+ 512.2 Example 89: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p 163-167°C
M+ 587.30
Example 90: X = 6-CH3O; X1 = 7-CH3O X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 134-136.5°C
M+ 577.40
Example 91: X = 6-CH3O; X1 - 7-CH3O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 211-213°
M+ 591.20
Example 92: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 214-216°C
M 591.30
Example 93: X = 6-CH3; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 192-194°C
M+ 499.20
Example 94: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H;
R3NR4 = m.p. 155-156°C
M+ 478.00
Example 95: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1, Q2 = H;
R3NR4 = m.p. 225-235°C
M+ 500.00
Example 96: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = C2H5O(CH2)2NH m.p. 185-186°C
M+
Example 97: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 240-242°C
M+ 560.00
Example 98: X 6-CH3O; X1 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = m.p. 238.5-240°C
M+ 545.00
Example 99: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 232-233°C
M+ 561.00
Example 100: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 229-230°C
M+ 572.00
Example 101: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 165-168 dec°C
M+ 628.00
Example 102: X = 6-CH3O; X1 = 7-CH3O; X = H; Q, Q1,
Q = H;
R3NR4 = m.p. 206-210°C
M+ 469.30
Example 103: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O;
R3NR4 = m.p. 200-202ºC
M+ 591.00
Example 104: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = M+ 548.30
Example 105 : X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O ; Q1 = 7-CH3O; Q2 = H;
R3NR4 = - m.p. 168-170°C
M+ 582. 30
Example 106 : X = 6-CH3O; X1 = 7-CH 3O; X2 = H;
Q = 6-CH3O ; Q1 = 7-CH3O; Q2 = H;
R3NR4 = (CH3OCH2CH2 ) 2 ) N- m.p . ºC
M 513 . 00
EXAMPLE 107
2-(3,4-Dimethoxyphenethylamino)-4-(2,3,4,5-tetrahydro- 2-benzoazep-2-yl)-6,7-dimethoxyquinazoline hydro- chloride (I: X = 6-CH3O; X1 = 7-CH3O; R1R2N = 2,3,4,5- tetrahydro-2-benzazep-2-yl;
R3 = 3,4-(CH3O)2C6H3(CH2)2-; and R4 = H)
A. 2-chloro-4-(2,3,4,5-tetrahydrobenzazep-2-yl)-6,7- dimethoxyquinazoline
A mixture of 1.0 g of 2,3,4,5-tetrahydro-2- benzazepine, 1.76 g of 2,4-dichloro-6,7-dimethoxyquina- zoline and 1.0 g of triethylamine in 25 ml of methylene chloride was stirred at room temperature under nitrogen for three hours. An additional 290 mg of the
benzazepine was added and stirring continued over 48
hours. The reaction mixture was diluted with 100 ml of methylene chloride and the organic solution washed successively with 1N hydrochloric acid (3 x 75 ml), water (2 x 75 ml), a saturated sodium bicarbonate solution (2 x 75 ml), water (2 x 75 ml) and a brine solution (1 x 75 ml). The organic phase was separated, dried over sodium sulfate and concentrated to a foam, 2.15 g. The residue was treated with reluxing methanol and cooled in a refrigerator. The resulting solids were filtered and dried, 1.84 g. A small sample was recrystallized from methanol, m.p. 164-165°C.
B. 2-(3,4-dimethoxyphenethylamino)-4-(2,3,4,5-tetra- hydrobenzazep-2-yl)-6,7-dimethoxyquinazoline hydrochloride
A mixture of 1.109 g of the product of Example 107A, 543 mg of 3,4-dimethoxyphenethylamine and 387 mg of diisopropylethylamine in 1.1 g ethoxyethoxyethanol was stirred under nitrogen at 170°C for five hours.
The reaction mixture was cooled to room temperature and diluted with 5 ml of methylene chloride. This solution was chromatographed without pressure on 60 g of silica gel using methylene chloride as the eluant, taking 15 fractions. Fractions 3-6 were combined and the elution continued under pressure with 2% methanol-methylene chloride, taking 14 fractions. Fractions 8-12 were combined and concentrated to give an oil which was dissolved in 6 ml of 1N hydrogen chloride in methanol. The resulting solids were filtered and dried, 679 mg, m.p. 226-228°C. Fractions 3-6 when carried through the same procedure gave 170 mg of the hydrochloride salt.
Anal. Calc'd for C30H34N4O4 · HCl: C, 65.4; H,
10.2; N, 6.4..
Found: C, 65.3; H, 10.1; N, 6.5.
EXAMPLES 108-138
Employing the procedure of Example 107 and starting with the appropriate reagents, the following compounds were prepared:
Example 108: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H, m = 0; p = 1;
NR3R4 =
m.p. 205-206°C M+ 531.2.
Example 109: X = 6-CH3O; X = 7-CH3O X2 = H; R, R5 = H; Q, Q1 = H; Q2 = 8-CH3O; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3 (CH2)2NH
m.p. 187-188°C M+ 531.0.
Example 110: X = 6-CH3; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 156-157°C M+ 489.0.
Example 111: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 5-CH3O; Q1 = 6-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 175-177°C
M+ 561.1.
Example 112: X = 6-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 241-242°C
M+ 509.03.
Example 113: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 166-167°C
M+ 509.0.
Example 114: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 = 6-CH3O; Q2 = H; R, R5 = H; m = 0;
p = 1; R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 209°C
M+ 561.27.
Example 115: X = 5-Cl; X1, X2 - H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 106-107°C
M+ 535.3.
Example 116: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 200-202°C
M+ 535.20.
Example 117: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O; m - 0; p = 1; R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 194.5-195.5°C
M+ 561.0.
Example 118: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 197-198°C
M+ 531.4.
Example 119: X = 6-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 214-215°C
M+ 535.40.
Example 120: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 178-179°C
M+ 531.4.
Example 121: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4(CH2)2NH
m.p. 178-179°C
M+ 505.3.
Example 122: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 2-I-4,5-(CH3O)2C6H2(CH2)2NH
m.p. 216-217°C (free base)
M+ 687.0.
Example 123: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O; m = 0; p = 1; R3R4N = 2-ClC6H4(CH2)2NH
m.p. 197-198°C
M+ 547.1.
Example 124: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q = 6-F; Q1, Q2 = H; m = 0; p = 1; R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 215-217°C
M+ 548.6.
Example 125: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q1 = H; Q2 = 7-CH3; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 182-183°C
M+ 515.3.
Example 126: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q1, Q2 = H; m = 1; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 222-223°C
M+ 515.3.
Example 127: X = 6-CH3O; X = 7-CH3O; X2 = H; R, R5 = H; Q, Q1, Q2 = H; m = 1; p = 1;
R3R4N = 2-ClC6H4(CH2)2NH
m.p. 218-219°C M+ 489.2.
Example 128: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4,5- (CH3O)3C6H2(CH2)2NH
m.p. 142-150°C
M+ 591.4.
Example 129: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = H;
R5 = 3,4-(CH3O)2C6H3CH2; Q = 6-CH3O; Q1 = 7-CH3O;
Q = H; m = 0; p = 1; R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 234-235°C
M+ 671.2.
Example 130: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = H;
R5 = 3,4-(CH3O)2C6H3CH2; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; m = 0; p = 1; R3R4N = 2, 3- (CH3O)2C6H3 (CH2)2NH m.p. 144-145°C
M+ 697.3.
Example 131: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q, Q1, Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 120-123°C
M+ 531.2.
Example 132: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q, Q1, Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 206-208°C
M+ 531.6.
Example 133: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q1, Q2 = H; m = 1; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 217-219°C M+ 515.5.
Example 134: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q2 = H; Q1 = 7-NH2; m = 1; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 213-217°C (free base) M+ 530.2.
Example 135: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = H; R-. = 3,4-(CH3O)2C6H3CH2; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; m = 0; p = 1; R3R4N = 3 ,4- (CH3O)2C6H3 (CH2)2NH m.p. 208-209°C
M+ 711.4.
Example 136: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O; m = 0; p = 1; R3R4N = 3, -(CH3O)2C6H3CH (CH3O) (CH2)2NH m.p. 159-161°C (free base)
M+ 621.4.
Example 137: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 5-OH; Q1 = 6-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 190-200°C
M+ 547.0.
Example 138: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 2-Br-4,5-(CH3O)2C6H2(CH2)2NH
m.p. 176-179°C
M+ 641.0.
Example 139: X = 5-CH3; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 141-142°C M+ 515.0.
EXAMPLES 140-147
Using the procedure of Example 107 and starting with the necessary reagents, the following compounds were prepared:
Example 140: X-CH3O; X1 - 7-CH3O; X2 = H; R1R2N R3R4N =
m.p. 204-207°C M+ 545.2.
Example 141: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
C2H5O(CH2)O R3R4 = 2, 4- (CH3O)2C6H3CH2NH;
m.p. 117-119° (free base) M+ 527.0.
Example 142: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
R3R4N = 2,4-(CH3O)2C6H3CH2NH;
m.p. 146-147°C (free base) M+ 621.4.
Example 143: X, X1, X2 = H; R1R2N = C6H11NH-;
R3R4N = C6H11NH;
m.p. 162-165°C (free base)
M+ 325.0.
Example 144: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
m.p. 215-217°C (free base) M+ 591.0.
Example 145: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N = 3 4
v
m.p. 220°C;
M+ 507.0.
Example 146: X = 6-N(CH3)2; X1 X2 = H; R1R2N =
; R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH;
m.p. 193.5-194.5°C M+ 544.3.
Example 147: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
R3R4N = ;
m.p. 156-158°C M+ 579.3.
PREPARATION A
Employing the procedure of Example 1A and starting with appropriate reagents, the following intermediates were prepared:
Compound 1: X = 6-CH3O; X1 = 7-C3H7O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
120-121°C.
Compound 2: X = 6-C2H5O; X 1 = 7-C2H5O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
161-162°C.
Compound 3: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H; R, R5 = H; m.p. 169-171°C.
Compound 4: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
183-186°C.
Compound 5: X, X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; R, R5 = H;; m.p. 126-126.5°C.
Compound 6: X = 6-CH3O; X1 = 7-CH3O; X2 = 8-CH3O;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
130-131°C.
Compound 7: X = 6-CH3O X1 = 7-C-H3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O Q2 = H;
R5 = 3,4-(CH3O)2C6H3CH2 R = H; m.p. 154-156.5°C.
Compound 8: X = 6-CH3O X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R, R5 = H ; m.p . 162-163 ºC . Compound 9 : X = 6-CH3O; X1 , X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 - H; R, R5 = H ; m.p . 132-134 °C.
Compound 10: X = 6-CH3; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 133-135°C.
Compound 11: X, X1, X2 = H, Q, Q1, Q2 = H; R, R5 = H; m.p. 130-131°C.
Compound 12: X = 6-F; X1 = 7-F; X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 219-220°C.
Compound 13: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q,
Q2 = H; Q1 = 7-NO2; R, R5 = H; m.p. 210-212°C.
Compound 14: X, X1 = H; X2 = 8-CH3O; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 147-149°C.
Compound 15: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1, Q2 = H; R, R5 = H; m.p. 181-184°C.
Compound 16: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 = 6-CH3O; Q2 = 7-CH3O; R, R5 = H; m.p.
152-153°C.
Compound 17 : X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 , Q2 = H; R, R5 = H; m. p . 144. 5-146 °C .
Compound 18 : X = 6-CH3O; X1 = 7-CH3O ; X2 = H;
Q = 7-NH2 ; Q1 , Q2 = H; R, R5 = H; m. p . 123-126 °C .
Compound 19: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 7-Cl; Q1, Q2 = H; R, R5 = H; m.p. 187-189°C.
Compound 20: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = 8-CH3O; R = C2H5O;
R5 = H; m.p. 150-153°C.
Compound 21: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R = CH3O; R5 = H; m.p.
138-140ºC.
Compound 22: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1, Q2 = H; R = C2H5O; R5 = H; m.p.
140-142°C.
Compound 23: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R = C2H5O; R5 = H; m.p.
161-164°C.
Compound 24: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = H; Q2 = 8-CH3O; R, R5 = H; m.p.
159-161°C.
Compound 25: X = H; X1 = 7-CH3O; X2 = 8-CH3O;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
143-143.5°C.
Compound 26: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = 8-CH3O; R, R5 = H; m.p.
152-153°C.
Compound 27: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 7-CH3; Q1, Q2 = H; R, R5 = H; m.p. 169-170°C.
Compound 28: X = 5-Cl; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 161-162°C.
Compound 29 : X = 6-Cl ; X1 , X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H ; m. p . 144-145°C .
Compound 30: X = 6-CH3O; X 1= 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 = 6-CH3O; Q2 = H; R, R5 = H;
m.p. 138.5-139°C.
Compound 31: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-OH; Q1 = 6-CH3O; Q2 = H; R, R5 = H;
m.p. 221-223°C.
Compound 32: X = 5-CH3; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 174-175°C.
Compound 33: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R = CH3O; R,. = H;
m.p. 138-140°C.
Compound 34: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q,
Q1 = H; Q2 = 8-CH3O; R, R5 = H; m.p. 204-205°C.
Compound 35: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H; R = CH3O; R5. = H; m.p. 162-165°C.
Compound 36: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = 6-F;
Q1, Q2 = H; R = CH3O; R5 = H; m.p. 155-157°C.
Compound 37: X = 6-N(CH3)2; X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; R, R5 = H; amorphous.
Compound 38: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = 6-F;
Q1, Q2 = H; R = CH3O; R5 = H; m.p. 195-197°C.
PREPARATION B
The procedure of Example 1A was repeated starting with the required materials to give the following intermediates:
Compound 39: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
m.p. 241-243°C.
Compound 40: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R1R2N = C2H5O(CH2)2 m.p. 91-94°C.
Compound 41: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N=
m.p. 149-150°C
Compound 42: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
Compound 43: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N = m.p. 174-176°C.
Compound 44: X = 6-CH3O; X1 = 7-CH3O; X = H; R1R2N = m.p. 300°C.
Compound 45: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
Compound 46: X, X1, X2 = H, R1R2N = C6H11NH; m.p. 85-89°C.
Claims
1. A compound of the formula
and a pharmaceutically acceptable acid addition salt thereof wherein X and X1 are each hydrogen, alkyl having one to four carbon atoms, alkoxy having one to four carbon atoms, bromo, iodo, nitro, amino, alkylamino having one to three carbon atoms, (CH3)2S⊕, aminomethyl, methylsulfinyl, dialkylaminomethyl having three to seven carbon atoms, methylthio, hydroxymethyl, benzoylamino, substituted benzoylamino wherein said substituent is azido, methoxy, methyl, fluoro, chloro or trifluoromethyl, alkanoylamino having two to four carbon atoms, 4-methylpiperazino, morpholino, thiomorpholino, piperazino, piperidino, pyrrolidino, dialkylamino having two to six carbon atoms, fluoro or chloro; X2 is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to four carbon atoms; X and X1 together are ethylenedioxy or methylenedioxy; R1 is alkoxylalkyl said alkoxy having from one to three carbon atoms and said alkyl having two to three carbon atoms, cycloalkyl having three to seven carbon atoms, alkyl having one to four carbon atoms or benzodioxan-2-ylmethyl; R2 is hydrogen, alkyl having one to eight carbon atoms or benzyl; R1 and R2 when taken together with the nitrogen atom to which they are attached form
(a) a moiety of the formula
wherein Q is hydrogen, alkoxy having one to three carbon atoms, hydroxy, alkanoylamino having two to four carbon atoms, alkyl having one to three carbon atoms, bromo, iodo, fluoro, chloro, nitro, morpholino, amino, alkylamino having one to three carbon atoms or dialkylamino having two to six carbon atoms, Q1 is hydrogen, fluoro, chloro, bromo, alkyl having one to three carbon atoms or alkoxy having one to three carbon atoms and Q2 is hydrogen or alkoxy having one to three carbon atoms, Q1 and Q2 together are ethylenedioxy or methylenedioxy, R is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to three carbon atoms, m is an integer of 0-2, p is an integer of 1-2, R5 is hydrogen or dialkoxybenzyl said alkoxy having one to three carbon atoms and R and R5 together are alkylene having one to three carbon atoms,
(b) 1,2,3,4-tetrahydro-beta-carbol-2-yl
(c) piperidino of the formula wherein R6 is pyridylmethoxy, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having from two to three carbon atoms or benzoxazol-2- ylmethyl
(d) octahydroisoindol-2-yl or
(e) decahydroisoquinol-2-yl;
R3 is
(a) cycloalkyl having three to seven carbon atoms, (b) benzodioxan-2-ylmethyl,
(c) aralkyl of the formula wherein n is an integer of 1 or 0, W is 0, S or a chemical bond, A is alkylene having one to four carbon atoms, Y is hydrogen, alkyl having one to three carbon atoms, alkoxy having one to three carbon atoms, fluoro, chloro, bromo, hydroxy, benzyloxy, nitro, dimethylamino or amino, Y1 is hydrogen, alkoxy having one to three carbon atoms, chloro, fluoro, hydroxy or benzyloxy, Y2 is hydrogen or alkoxy having one to three carbon atoms and Y and Y1 together are ethylenedioxy or methylenedioxy,
(d) aralkyl of the formula wherein R7 is hydroxy, alkoxy having one to three carbon atoms or C6H5(CH2)t-, n is 1, t is an integer of 0 or 1, A is alkylene having one to four caraon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(e) pyridylalkyl said alkyl having from one to four carbon atoms,
(f) alkoxyalkyl said alkoxy having from one to three carbon atoms and said alkyl having two the three carbon atoms,
(g) indolylalkyl of the formula
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(h) tetrahydronaphthalene of the formula wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(i) aralkanol of the formula wherein W is O, S or a chemical bond and Q3 is hydrogen or alkoxy having one to three carbon atoms,
(j) 2,3-dihydro-2-hydroxyinden-1-yl,
(k) aracycloalkyl of the formula
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(1) indene of the formula wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(m) naphthyl or (n) 1-methylpyrrol-2-yl;
R4 is hydrogen or alkyl having one to eight carbon atoms, and R3 and R4 when taken together with the nitrogen atom to which they are attached form
(a) a tetrahydro isoquinoline of the formula wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(b) piperidino of the formula
wherein R8 is benzyl, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having two to three carbon atoms or alkyl sulfonamide of the formula wherein R9 is alkyl having from one to four carbon atoms,
(c) 3-methyl-3-phenylpiperidino or
(d) piperazino of the formula wherein R10 is hydrogen, alkoxycarbonyl having from two to six carbon atoms, acyl having one to six carbon atoms, hydroxyalkoxy carbonyl having three to six carbon atoms, furoyl, benzoxazol-2-yl, pyrimid-2-yl or benzodioxan-2- carbonyl.
2. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
wherein Q1 is alkoxy having one to three carbon atoms, R and R5 are each hydrogen, p is 1 and m. is 0, R3 is aralkyl of the formula
wherein Y1 and Y2 are each methoxy, n is 0, W is a chemical bond and A is ethylene and R4 is hydrogen.
3. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 5-hydroxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2-methoxy and Y2 is 3-methoxy.
4. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
5. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2-methoxy and Y2 is 3-methoxy.
6. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q and Q2 are each hydrogen, Q1 is 6-methoxy, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
7. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 5-methoxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
8. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Q2 is hydrogen, Y is 2-bromo, Y1 is 4-methoxy and Y2 is 5-methoxy.
9. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
10. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
11. A compound of claim 1, wherein X1 and X2 are each hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
wherein Q and Q1 are each alkoxy having one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1 and m is 0, R3 is aralkyl of the formula
wherein Y2 is hydrogen, n is 0, W is a chemical bond and A is ethylene and R4 is hydrogen.
12. The compound of claim 11, wherein X is 5-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Y is 2-chloro and Y1 is hydrogen.
13. The compound of claim 11, wherein X is 5-chloro, Q is 6-methoxy, Q1 7-methoxy, Y is 2-chloro and Y1 is hydrogen.
14. The compound of claim 11, wherein X is 5-methyl, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and Y1 is 4-methoxy.
15. The compound of claim 11, wherein X is 6-dimethyl- amino, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and
Y1 is 4-methoxy.
16. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
wherein Q2 is hydrogen, R5 is hydrogen and p is 1-2, R3 is aralkyl of the formula
wherein Y and Y1 are each alkoxy having one to three carbon atoms, Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R4 is hydrogen.
17. The compound of claim 16, wherein X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 1, R is methoxy, m is 0, Y is 2-methoxy and Y1 is 3-methoxy.
18. The compound of claim 16, wherein X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 2, R is hydrogen, m is 0, Y is 3-methoxy and Y1 is 4-methoxy.
19. The compound of claim 16, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-amino, Q1 is hydrogen, R is hydrogen, m is 0, p is 1, Y is 3-methoxy and Y1 is 4-methoxy.
20. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
wherein Q and Q1 are each alkoxy having one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula wherein Q3 and Q4 are each alkoxy having one to three carbon atoms, R7 is methoxy, n is 1, A is methylene and R4 is hydrogen.
21. The compound of claim 20, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q3 is 2-methoxy and Q4 is 4-methoxy.
22. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
wherein Q1 and Q2 are each hydrogen, R5 is hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
wherein Q3 and Q4 are each alkoxy having one to three carbon atoms, R7 is methoxy, n is 1, A is methylene and R4 is hydrogen.
23. The compound of claim 22, wherein X is 6-methoxy,
X1 is 7-methoxy, Q is 6-fluoro, R is methoxy, Q3 is 2-methoxy and Q4 is 3-methoxy.
24. A compound of claim 1, wherein X1 is alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
wherein Q and Q1 are each alkoxy having one to three carbon atoms, Q2 is hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
wherein Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R4 is hydrogen.
25. The compound of claim 24, wherein X is 6-chloro,
X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, R and R5 are each hydrogen, Y is 3-methoxy and Y1 is 4-methoxy.
26. A method of inhibiting a P-glycoprotein in a mammal in need of such treatment which comprises adminis tering to said mammal a P-glycoprotein inhibiting amount of a compound according to claim 1.
27. A method of claim 26, wherein the mammal is a human suffering from cancer and said compound is administered before, with or after the administration to said human of an anticancer effective amount of a chemotherapeutic agent.
28. A pharmaceutical composition for administration to a mammal which comprises a P-glycoprotein inhibiting amount of a compound of claim 1, a pharmaceutically acceptable carrier and, optionally, an anticancer effective amount of a chemotherapeutic agent.
29. A process for preparing a compound of the formula
and a pharmaceutically acceptable acid addition salt thereof wherein X and X1 are each hydrogen, alkyl having one to four carbon atoms, alkoxy having one to four carbon atoms, bromo, nitro, iodo, methylsulfinyl, (CH3)2S⊕, amino, alkylamino having one to three carbon atoms, methylthio, aminomethyl, dialkylaminomethyl having three to seven carbon atoms, hydroxymethyl, morpholino, thiomorpholino, piperazino, benzoylamino, substituted benzoylamino wherein said substituent is azido, methoxy, methyl, fluoro, chloro or trifluoromethyl, alkanoylamino having two to four carbon atoms, 4-methylpiperizino, piperidino, pyrrolidino, dialkylamino having two to six carbon atoms, fluoro or chloro; X2 is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to four carbon atoms; X and X1 together are ethylenedioxy or methylenedioxy; R1 is cycloalkyl having three to seven carbon atoms, alkoxyalkyl said alkoxy having one to three carbon atoms and said alkyl having two to three carbon atoms, alkyl having one to four carbon atoms or benzodioxan-2-ylmethyl; R2 is hydrogen, alkyl having one to eight carbon atoms or benzyl; R1 and R2 when taken together with the nitrogen atom to which they are attached form
(a) a moiety of the formula
wherein Q is hydrogen, alkoxy having one to three carbon atoms, hydroxy, alkanoylamino having two to four carbon atoms, alkyl having one to three carbon atoms, bromo, iodo, fluoro, chloro, nitro, amino, morpholino, alkylamino having one to three carbon atoms or dialkylamino having two to six carbon atoms, Q1 is hydrogen, fluoro, chloro, bromo, alkyl having one to three carbon atoms or alkoxy having one to three carbon atoms and Q2 is hydrogen or alkoxy having one to three carbon atoms, Q1 and Q2 together are ethylenedioxy or methylenedioxy, R is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to three carbon atoms, m. is an integer of 0-2, p is an integer of 1-2, R5 is hydrogen or dialkoxybenzyl said alkoxy having one to three carbon atoms and R and R5 together are alkylene having one to three carbon atoms,
(b) 1,2,3,4-tetrahydro-beta-carbol-2-yl,
(c) piperidino of the formula wherein R6 is pyridylmethoxy, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having from two to three carbon atoms or benzoxazol-2- ylmethyl
(d) actahydroisoindol-2-yl or
(e) decahydroisoquinol-2-yl; R3 is
(a) cycloalkyl having three to seven carbon atoms,
(b) benzodioxan-2-ylmethyl,
(c) aralkyl of the formula
wherein n is an integer of 1 or 0, W is O, S or a chemical bond, A is alkylene having one to four carbon atoms, Y is hydrogen, alkyl having one to three carbon atoms, alkoxy having one to three carbon atoms, fluoro, chloro, bromo, hydroxy, benzyloxy, nitro, dimethylamino or amino, Y1 is hydrogen, alkoxy having one to three carbon atoms, chloro, fluoro, hydroxy or benzyloxy, Y2 is hydrogen or alkoxy having one to three carbon atoms and Y and Y1 together are ethylenedioxy or methylenedioxy,
(d) aralkyl of the formula wherein R7 is hydroxy, alkoxy having one to three carbon atoms or C6H5(CH2)t-, n is 1, t is an integer of 0 or 1, A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(e) pyridylalkyl said alkyl having from one to four carbon atoms,
(f) alkoxyalkyl said alkoxy having from one to three carbon atoms and said alkyl having two to three carbon atoms, (g) indolylalkyl of the formula
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(h) tetrahydronaphthalene of the formula wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(i) aralkanol of the formula wherein W is O, S or a chemical bond and Q3 is hydrogen or alkoxy having one to three carbon atoms,
(j) 2,3-dihydro-2-hydroxyinden-1-yl,
(k) aracylcoalkyl of the formula
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(1) indene of the formula wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(m) naphthyl or
(n) 1-methylpyrrol-2-yl;
R4 is hydrogen or alkyl having one to eight carbon atoms, and R3 and R4 when taken together with the nitrogen atom to which they are attached form
(a) a tetrahydro isoquinoline of the formula
wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(b) piperidino of the formula wherein R8 is benzyl, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having two to three carbon atoms or alkyl sulfonamide of the formula wherein R9 is alkyl having from one to four carbon atoms, (c) 3-methyl-3-phenylpiperidino or
(d) piperazino of the formula wherein R10 is hydrogen, alkoxycarbonyl having from two to six carbon atoms, acyl having one to six carbon atoms, hydroxyalkoxy carbonyl having three to six carbon atoms, furoyl, benzoxazol-2-yl, pyrimid-2-yl or benzodioxan-2- carbonyl, which comprises reacting a compound of the formula
wherein R1, R2, X, X1 and X2 are defined with a compound of the formula
R3R4NH where R3 and R4 are defined in a reaction-inert solvent containing one equivalent of an amine-acid scavenger at a reaction temperature of 100-200ºC until the reaction is substantially complete.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60998690A | 1990-11-06 | 1990-11-06 | |
US609986 | 2000-07-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
AU9059291A AU9059291A (en) | 1992-05-26 |
AU644035B2 AU644035B2 (en) | 1993-12-02 |
AU644035C true AU644035C (en) | 1994-08-18 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0556310B1 (en) | Quinazolines derivatives for enhancing antitumor activity | |
EP0572437B1 (en) | 2,4-diaminoquinazolines derivatives for enhancing antitumor activity | |
KR102630069B1 (en) | Apoptosis-inducing agent | |
US8314085B2 (en) | Agent for overcoming resistance to anti-cancer agent | |
EP0580753B1 (en) | Pyrimidine derivatives for enhancing antitumor activity | |
WO1993017021A1 (en) | Heterocyclic compounds for enhancing antitumor activity | |
EP0339976B1 (en) | Anti-tumour agents | |
AU644035C (en) | Quinazolines derivatives for enhancing antitumor activity | |
US5491234A (en) | Pyrimidine derivatives for enhancing antitumor activity | |
CN1990470B (en) | Phthiobuzonum derivative, its manufacturing process, pharmaceutical combination and uses thereof | |
KR100566194B1 (en) | Novel 3-nitropyridine derivatives and pharmaceutical compositions comprising the same | |
RU2782469C2 (en) | Apoptosis-inducing agents |